Surgery vs observation for liver cancer that responded to drug therapy
Part of Cancer, Digestive system clinical trials.
This trial looks at whether people with an initially untreatable liver cancer that has shrunk or disappeared after drug therapy should have surgery or just continue monitoring. It aims to see which approach helps people live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your liver cancer was first considered too advanced for surgery, but you had drug therapy that made it completely inactive or gone as seen on scans.
- Your doctor now thinks the cancer can be surgically removed, and you are healthy enough for surgery.
- Your liver function is good enough (Child-Pugh A or B) and your overall health is fairly good (ECOG score 0 or 1).
- You have not had other cancers in the last 5 years (except some easily treated ones like skin or early thyroid cancer).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two options for people whose liver cancer has completely disappeared after treatment: having surgery to remove the remaining affected area, or continuing to monitor closely without immediate surgery. It aims to find out which approach helps people live longer and live better.
This trial tests whether giving a combination of chemotherapy, immunotherapy, and targeted therapy before surgery can shrink liver cancer and reduce the chance of it coming back, compared to going straight to surgery. The treatment includes medicines like pembrolizumab (sintilimab) and a drug that blocks blood vessel growth (bevacizumab).
This trial combines surgery to remove liver tumors with two drugs, camrelizumab (an immunotherapy that helps your immune system fight cancer) and apatinib (a targeted therapy that may cut off the tumor's blood supply). It aims to see if this combination helps people with advanced liver cancer that has spread outside the liver (but not to the brain) and who have chosen not to have other standard treatments like TACE or radiation. Participating could potentially control the spreading cancer and improve outcomes.
This trial looks at how well certain initial treatments (like targeted therapy, immunotherapy, or liver-directed procedures) work in people with liver cancer who have not had surgery yet. It aims to see if these treatments can shrink the tumor enough to allow removal later.
This trial tests a combination of treatments before and after surgery for liver cancer that can be removed. The goal is to see if adding targeted therapy and immunotherapy can reduce the risk of cancer coming back.
This trial tests whether a combination of three drugs given before surgery can help shrink liver cancer and improve outcomes for patients whose tumors can be removed. It is for people with intermediate-stage liver cancer that is still operable.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.